This company has been acquired
Acer Therapeutics (ACER) Stock Overview
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ACER Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Acer Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.80 |
| 52 Week High | US$4.56 |
| 52 Week Low | US$0.55 |
| Beta | 0.44 |
| 1 Month Change | -2.73% |
| 3 Month Change | 21.88% |
| 1 Year Change | -30.04% |
| 3 Year Change | -70.42% |
| 5 Year Change | -96.75% |
| Change since IPO | -91.99% |
Recent News & Updates
Recent updates
Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment
Oct 05Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU
Aug 12FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy
Jul 28Acer resubmits U.S. marketing application for urea cycle disorder therapy
Jul 18Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth
Feb 11
Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases
Aug 31We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate
May 20Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares
Feb 25Shareholder Returns
| ACER | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.4% | -0.6% | 3.3% |
| 1Y | -30.0% | 39.1% | 28.1% |
Return vs Industry: ACER underperformed the US Pharmaceuticals industry which returned -4.4% over the past year.
Return vs Market: ACER underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| ACER volatility | |
|---|---|
| ACER Average Weekly Movement | 32.3% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ACER's share price has been volatile over the past 3 months.
Volatility Over Time: ACER's weekly volatility has increased from 23% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 30 | Chris Schelling | www.acertx.com |
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company’s pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder.
Acer Therapeutics Inc. Fundamentals Summary
| ACER fundamental statistics | |
|---|---|
| Market cap | US$19.68m |
| Earnings (TTM) | -US$38.76m |
| Revenue (TTM) | n/a |
Is ACER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACER income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$38.76m |
| Earnings | -US$38.76m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -96.4% |
How did ACER perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/20 07:17 |
| End of Day Share Price | 2023/11/17 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Acer Therapeutics Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Constantine Davides | D. Boral Capital LLC. |
| Vernon Bernardino | H.C. Wainwright & Co. |